Clinical trials for the expansion of indications of endoscopic ultrasound-guided radiofrequency ablation in patients with pancreatic tumors

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0005590

Enrollment

Registered

2020-11-12

Start date

2020-11-15

Completion date

Unknown

Last updated

2020-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : A. Before EUS-RFA, all patients were checked screening test, including blood tests, tumor markers, Karnofsky Performance Status Scale, imaging studies. B. The EUS-RFA procedure varies

s opinion, patients received an examination at 8 days or 12 days later EUS-RFA D. At 6 month, blood tests, tumor markers, Karnofsky Performance Status Scale,pain level by treatment using pain assessme

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Persons who are able to understand clinical trials of Adults under the age of 20 and under 80 years old who are voluntarily agreed to participate in this clinical trial, voluntarily agreeing to sign consent for this clinical trial. 2. Patients who have been diagnosed with tumors of pancreas and pancreatic tumors using biopsy. 3. Patients who are inoperable or can be operated but not wanted 4. Estimated expectation period of 6 months or more. 5. tumor is identified by CT, MRI or EUS 6. Patients with = 50 % of Karnofsky performance status 7. Patient whose results are normal in the blood coagulation test 8. Patients who follow the clinical trial procedure and comply with the visit schedule.

Exclusion criteria

Exclusion criteria: 1. Patient who can not see images of endoscopic ultrasonography. 2. Patients who are taking drugs that can cause bleeding, such as aspirin. 3. Chronic obstructive or restrictive chronic lung disease, including breathing difficulty during recess 4. Other serious diseases or medical conditions. 5. Other medical condition that may impair the ability of patients to participate in clinical trials. 6. Patients with significant neurologic or psychiatric disorder, such as dementia or strokes.

Design outcomes

Primary

Measure	Time frame
Assessment of changes in the size of pancreatic tumours in CT or MRI	—

Secondary

Measure	Time frame
Evaluation of pain level by treatment using pain assessment tool;Assessment of complications based on treatment via CT/MRI, blood tests and abnormal reactions.	—

Countries

Korea, Republic of

Contacts

Public ContactDongWan Seo

University of Ulsan

Outcome results